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Abstract. The present study sought to estimate the applicability 
of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), 
vascular endothelial growth factor A (VEGFA) expression and 
CD163+ tumor-associated macrophage (TAM) ratio as prog-
nostic factors in bladder cancer (BCa). A total of 127 patients 
with bladder urothelial cancer who underwent radical cystec-
tomy at Daping Hospital were recruited between January 2013 
and January 2017, including 45 cases of non-muscle inva-
sive BCa (NMIBC) and 82 of MIBC. Immunohistochemical 
detection of APE1, VEGFA and CD163, as well as multiple 
immunofluorescence staining for APE1, VEGFA, CD163 
and CD34, were performed on tissue samples. For APE1 and 
VEGFA, the staining was graded based on intensity (0-3), 
while CD163 was graded (0-3) based on the percentage of 
positively stained cells. The prognostic value of APE1, VEGF 
and CD163 was assessed using Kaplan-Meier and Cox regres-
sion analysis. The results suggested that in BCa, high APE1 
expression was associated with high VEGFA expression and 
more infiltration of CD163+ TAM. Furthermore, high expres-
sion of APE1 was associated with lymphovascular invasion 
of BCa, as well as reduced survival time. This indicates that 
APE1 may be associated with CD163+ TAM infiltration in 
BCa, with VEGFA as a possible influencing factor.
Introduction
Bladder cancer (BCa) is one of the most common types of 
urological cancer, resulting in ~150,000 deaths worldwide 
every year (1). Approximately 75% of new BCa cases present 
as non-muscle-invasive BCa (NMIBC) and up to 50% of them 
will recur with 20% of these recurring cases progressing (2). 
Treatment options for BCa vary based on the stage at diagnosis. 
For MIBC and recurrent NMIBC, radical cystectomy (RC) 
is usually the mainstay of treatment, where the goal is to 
provide optimal cancer control by removal of whole bladder 
tissue (3). Despite this, ~4-10% of patients are still susceptible 
to secondary urothelial tumors following RC and frequently 
have an adverse prognosis due to late diagnosis (4). Although 
numerous serum and urine biomarkers have been suggested, 
their precision and specificity still require further evidence (5). 
Therefore, identification of a novel molecular mechanism or 
biomarker that may provide a novel treatment option, retard 
the progression of Bca, improve the prediction of the prognosis 
of BCa may provide a significant benefit in terms of benefiting 
clinical treatment greatly.
Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) 
protein, also known as redox factor-1 (Ref-1), was originally 
identified as a multifunctional protein involved in DNA base 
excision repair (BER) and redox signaling. Previous studies 
have indicated that APE1 expression is not only significantly 
higher in multiple cancer types, including liver cancer, ovary 
cancer and osteosarcoma, but also highly associated with 
prognosis (6-8). Although APE1 was suggested as a urinary 
biomarker (5,9), its prognostic value in cancer tissue has not 
been verified with sufficient cases.
Previously, Sun and Nelson (10) suggested that the 
DNA repair gene APE1 is able to promote the production 
of a spectrum of cytokines, growth factors and proteases, 
including vascular endothelial growth factor (VEGF), by 
the DNA damage secretory program. In the tumor micro-
environment (TME), VEGF is secreted by tumor cells and 
diffuse through the tissue contributing to angiogenesis (11). 
Furthermore, VEGF has a role as an immunosuppressive 
gene, inducing a ‘tumor endothelial barrier’ to promote T-cell 
arrest, or the loss of T cell motility (12). In BCa, VEGF has 
been indicated to be associated with stage and recurrence. 
Wheeler et al (13) suggested that VEGF is able to recruit 
macrophages and polarize them to the M2 phenotype in the 
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decidua. This may provide a novel mechanism to how VEGF 
is able to worsen the clinical outcomes of BCa through 
tumor-associated macrophage (TAM) manipulation. The study 
of TAMs impacting the progression and metastasis of cancer 
has been fruitful. Alternatively activated M2 macrophages in 
TME are responsible for angiogenesis and tissue remodeling 
and feature an immunosuppressive phenotype, which may have 
an important role in tumor progression (14). In BCa, M2 type 
macrophages are usually associated with poor response to 
BCG therapy and may significantly limit its efficacy (15). Of 
note, in MIBC, TAMs mostly infiltrate into the tumor areas as 
opposed to stroma-tumor margins in NMIBC, which is associ-
ated with an unfavorable clinical outcome (16).
Therefore, the present study sought to evaluate the associa-
tion among the expression of APE1 and vascular endothelial 
growth factor A (VEGFA) and the infiltration of M2 macro-
phages, as detected via the M2 marker CD163, as well as their 
prognostic significance in BCa. To the best of our knowledge, 
the present study was the first to implicate APE1 as a key factor 
in the DNA damage response with polarization of TAM, laying 
a foundation for elucidating the mechanism of the recurrence 
of BCa and exploring the efficacy of immunotherapy for this 
neoplasm.
Materials and methods
Patients and data collection. A total of 167 patients with BCa 
subjected to radical cystectomy at Daping Hospital between 
January 2013 and January 2017 were recruited without any 
restriction by age or sex. Data collection was closed by 
May 2019. Those patients who did not have a reported event 
of death at the time of closure were included for calculation 
of the median follow-up time. Patient follow-up was usually 
performed every 3 months in the first year post‑surgery and 
then every 6 months. The cause of death was determined 
by chart review from patients' medical records or from 
the death certificate. The follow‑up time was 4‑78 months 
and the median follow-up time was 48 months. Cases with 
non-urothelial carcinoma types and patients who died of 
causes not associated with cancer were excluded, and cases 
without precise follow-up were also excluded, resulting in 
127 remaining cases. All subjects were from a Han Chinese 
population and were subjected to radical cystectomy at 
Daping Hospital (Chongqing, China) with the diagnosis 
made based on pathology. The general characteristics of 
the patients are summarized in Table SI. The median age 
was 64.25 years (range, 39-88 years). There were 45 cases 
of NMIBC and 82 cases of MIBC. In total, 10 cases were 
low-grade carcinoma and 117 were high-grade carcinoma, 
and 36 of the latter were indicated to have lymphovascular 
invasion (LVI). Regarding the smoking history, a person who 
had at least one pack of cigarettes/day for >1 year in his/her 
lifetime was regarded as having a positive smoking history; 
otherwise, they were considered as a non-smoker (17). The 
study was approved by the Ethics Committee of Daping 
Hospital (Chongqing, China).
Pathological evaluation and immunohistochemistry (IHC). 
Tumor tissues were fixed overnight in 4% paraformalde-
hyde, dehydrated, embedded in paraffin and sectioned into 
8-10 mm (RM2235; Leica Microsystems). Experienced 
pathologists blinded to the clinical outcomes reviewed these 
pathological specimens. The tumors were staged according 
to the 8th AJCC TNM staging classification (18). Grading 
was performed following the 1998 WHO/ISUP consensus 
classification (19). The presence of LVI was assessed in 
all specimens. IHC staining for APE1, VEGFA and CD163 
was conducted utilizing the following antibodies: APE1 
(1:2,000 dilution; mouse monoclonal; cat. no. ab194; Abcam), 
VEGFA (1:150 dilution; mouse monoclonal; cat. no. ab52917; 
Abcam) and CD163 (1:150 dilution; mouse monoclonal; cat. 
no. TA506388; Origene). Goat antibodies conjugated to horse-
radish peroxidase (HRP) (working solution, Kit-5030; MXB) 
was used as a secondary antibody, 3,3'-diaminobenzidine 
was used as a chromogenic substrate and the sections were 
counterstained with hematoxylin. The results were analyzed 
by an experienced pathologist (HX) blinded to the clinical 
outcomes. APE1 and VEGFA expression were graded based on 
the staining intensity of the nuclei and cytoplasm, respectively, 
in the tumor area. Necrotic areas were ignored. Grade 0 had 
the weakest staining and grade 3 had the strongest staining. In 
the evaluation of APE1 expression, grade 0-2 was considered 
to indicate low expression, while grade 3 was considered to 
indicate high expression. For VEGFA expression, grade 0-1 
was considered low expression, while grade 2-3 was consid-
ered as high expression. For CD163, the percentage of stained 
macrophages in the tumor stroma compared to the total 
number of nucleated stromal cells was scored using a scale 
from 0 to 100% and graded as follows: 0, 0-5%; 1, 6-30%; 
2, 31-50%; and 3, >50%. For evaluation purposes, grade 0-1 is 
considered as low TAM ratio, inversely grade 2-3 is considered 
as high ratio. The cutoff is set by mainly taking the median 
grade value in consideration.
Multiple immunofluorescence staining. Multiple immuno-
fluorescence staining was performed on paraffin‑embedded 
tissues. Sections of 4 µm thickness were cut from selected BCa 
tissues. The slides were deparaffinized in xylene, rehydrated 
and washed with tap water prior to boiling in Tris-EDTA buffer 
(pH 9, 643901; Klinipath) for epitope retrieval/microwave treat-
ment. Endogenous peroxidase was blocked using Antibody 
Diluent/Block (cat. no. 72424205; Perkin Elmer) and incubated 
at room temperature. Protein blocking was performed using 
Antibody Diluent/Block at 37˚C for 1 h. The slides were incu-
bated with primary antibodies to CD163 (1:150 dilution; cat. 
no. ZM0428; Zsbio), APE1 (1:2,000 dilution; cat. no. ab194; 
Abcam) and VEGFA (1:100 dilution; cat. no. ab52917; Abcam) 
for 1 h at 37˚C, and then incubated with antibody to CD34 
(cat. no. kit‑0004; MXB) at 4˚C overnight. Next, incubation 
with Opal Polymer HRP Ms+Rb (cat. no. 2414515; Perkin 
Elmer) was performed at 37˚C for 10 min. Tyramide signal 
amplification (TSA) visualization was performed with the Opal 
eight-color IHC kit (cat. no. NEL797B001KT; Perkin Elmer), 
containing fluorophores DAPI, Opal 690 (CD34), Opal 650 
(VEGFA), Opal 570 (APE1) and Opal 520 (CD163), as well as a 
TSA Coumarin system (cat. no. NEL703001KT; Perkin Elmer).
Slides were scanned using the Perkin Elmer Vectra 
(Vectra 3.0.5; Perkin Elmer). Multispectral images were 
unmixed using spectral libraries built from images of single 
stained tissues for each reagent using the inform Advanced 
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Image Analysis software (inForm 2.3.0; Perkin Elmer). A selec-
tion of 5-10 representative original multispectral images was 
used to train the inForm software (tissue segmentation, cell 
segmentation, phenotyping tool and positivity score). All the 
settings applied to the training images were saved within an 
algorithm to allow the inForm software (PerkinElmer; v2.3.0) 
batch analysis of multiple original multispectral images of the 
same tissue (20).
Statistical analysis. Data analysis was performed using SPSS 
(version 22; IBM, Corp.) and GraphPad Prism 7 (GraphPad 
Software, Inc.). Cumulative survival probabilities were 
estimated using the Kaplan-Meier method and differences 
between survival rates were tested for significance using the 
log-rank test. Univariate and multivariate Cox regression 
analyses were calculated using SPSS. Hazard ratios (HRs) and 
95% confidence intervals (95% CI) were used to present the 
associations of dependent and independent variables with the 
risk of mortality. The χ2 test was employed to assess differ-
ences between two groups. All tests were two-sided with 
a 95% CI and P<0.05 was considered to indicate statistical 
significance. Receiver operating characteristic (ROC) analysis 
was conducted for further evidence. Correlation of APE1, 
VEGFA and CD163 expression in muscle invasive bladder 
cancer tissues with multiple immunofluorescence staining was 
analyzed with Pearson correlation.
Results
Expression of APE1, VEGFA and CD163+ TAMs in BCa 
tissues. IHC was used to estimate the expression of APE1 
and VEGFA, as well as the ratio of CD163+ TAMs, and the 
association between each of them with the clinicopathological 
characteristics was determined. APE1 was mainly localized 
in the nuclei with a certain amount residing in the cytoplasm, 
whereas VEGFA appeared in the cytoplasm only (Fig. 1). 
Among the 127 patients, 62 (48.82%) and 67 (52.76%) exhib-
ited elevated levels of APE1 and VEGFA, respectively. The 
APE1 levels appeared to be associated with LVI (P=0.019) 
but not with the tumor stage or grade (Table SII). The levels 
of VEGFA were not associated with the tumor stage, grade 
or LVI. CD163+ TAMs were present in the tumor stroma 
and tumor islets. The tumor stroma included the papillary 
axis, lymphoid aggregates and the stroma. In certain speci-
mens, staining for CD163 was positive in the cytoplasm and 
membrane of tumor cells. Of the 127 cases, 62 (48.82%) had a 
high grade regarding CD163+ TAMs but this was not associ-
ated with the tumor stage, grade or LVI.
APE1 and VEGFA expression is correlated with the CD163+ 
TAM ratio in BCa. The correlation between the expres-
sion of APE1 and VEGFA and the proportion of CD163+ 
M2 macrophages was then assessed. The results suggested 
Figure 1. (A) Representative immunohistochemistry results for APE1, VEGFA and CD163 indicated that APE1 staining was mainly located in the nuclei and 
partly in the cytoplasm and VEGFA was present in the cytoplasm of tumor cells, while CD163 was expressed on the infiltrating macrophages (magnifica-
tion, x200). The staining was rated as 0, 1+, 2+ or 3+ based on intensity for APE1 and VEGFA and based on the percentage of positive cells for CD163. 
(B) Heatmap presentation of the gradings of APE1, VEGFA and CD163 among the 127 patients. VEGFA, vascular endothelial growth factor A; APE1, 
apurinic/apyrimidinic endodeoxyribonuclease 1.
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that high expression of APE1 in tumor cells was positively 
correlated with the grade regarding CD163+ TAMs (r=0.196, 
P=0.027), as well as with VEGFA expression (r=0.208, 
P=0.018). Furthermore, VEGFA expression was strongly 
correlated with the grade regarding CD163+ TAMs (r=0.408, 
P<0.001; Table SIII). To further assess the expression of APE1 
and VEGFA in BCa tissues and their correlation with the 
CD163+ TAM ratio, multiple immunofluorescence staining 
for APE1, VEGFA, CD163 and CD34 was performed. The 
results suggested that APE1 and VEGFA were co-expressed 
in tumor cells, and CD163+ TAMs were mostly distributed 
around the microvasculature of tumor stroma or between 
tumor cells (Fig. 2). Further analysis using inForm software 
suggested that APE1 expression is positively correlated with 
VEGFA and CD163 expression (Table SIV).
APE1 and CD163 are independent prognostic factors for 
OS in BCa. KM analysis revealed that high APE1 expres-
sion and a high CD163+ TAM ratio were associated with a 
shorter OS (Fig. 3). A univariate Cox regression analysis 
for the expression of APE1, VEGFA, CD163+ TAMs and 
clinical characteristics was performed, indicating that the 
T-stage (HR=8.279, 95% CI: 2.948-23.255, P<0.001), N-stage 
(HR=4.265, 95% CI: 2.262-8.045, P<0.001), LVI (HR=2.974, 
95% CI: 1.642-5.387, P<0.001), APE1 expression (HR=2.797, 
95% CI: 1.486-5.267, P=0.001) and CD163+ TAMs (HR=2.425, 
95% CI: 1.300-4.521, P=0.005) were associated with prognosis. 
In addition, a multivariate analysis for OS was performed by 
combining the marker panel and clinical variables, suggesting 
that the T-stage (HR=8.279, 95% CI: 2.948-23.255, P<0.001), 
N-stage (HR=4.265, 95% CI: 2.262-8.045, P<0.001), APE1 
expression (HR=2.797, 95% CI: 1.486-5.267, P=0.001) and 
CD163+ TAMs (HR=2.425, 95% CI: 1.300-4.521, P=0.005) 
were independent prognostic factors (Table I). Area under the 
curve are shown in Table SV.
Discussion
Multiple nomograms and models have been constructed in the 
past to predict the outcomes of Bca (21). Accurate risk stratifica-
tion may provide a marked benefit for patients with NMIBC that 
qualify for early RC, as well as for patients with MIBC, who gain 
from perioperative chemotherapy. The identification of new char-
acteristics will substantially increase the fidelity of such models.
The presence of LVI, defined as the presence of tumor cells 
in the lymphatic vessel and in vascular walls, has been reported 
to be of prognostic value in patients with Bca. Evidence 
suggests that LVI is a characteristic of biologically and clini-
cally aggressive BCa and may be of prognostic value. In the 
present study, 34 out of 127 patients were identified to have 
LVI, 32 of which had MIBC and 2 had NMIBC (Table SII). In 
addition, the presence of LVI is associated with an unfavorable 
prognosis. This is consistent with other studies (22).
Aromatic amines are well-known risk factors for BCa (23). 
Interaction between environmental exposure and genetic 
susceptibility may markedly increase DNA damage and thus 
trigger urothelial precancerous events; therefore, prompt 
elimination of such damage counteracts malignant transfor-
mation. The BER pathway has a critical role in DNA repair 
mechanisms by removing nucleobase modifications by oxida-
tion, alkylation and deamination, and also repairs backbone 
single-strand DNA breaks (24). The enzyme APE1 has a 
mainframe role in BER by correcting apurinic/apyrimidinic 
sites, which are pre-mutagenic lesions able to stall DNA 
replication forks. Studies have indicated above-basal expres-
sion levels of APE1 and other DNA repair pathway proteins 
Figure 2. Multiple immunofluorescence staining for APE1, VEGFA, CD163 and CD34 in bladder cancers. (A) Representative sample with high expression of 
APE1 and VEGFA in which the intratumor CD163-labeled M2 macrophages are easily distinguishable. (B) Example of a sample with high expression of APE1 
and VEGFA in which the CD163-labeled M2 macrophages are easily distinguishable in the tumor stroma. (C) Representative sample with low expression of APE1 
and VEGFA, in which the CD163-labeled M2 macrophages are less distinguishable. APE1-positive staining in tumor epithelial cells displayed as orange and 
VEGFA‑positive staining in tumor epithelial cells was cyan, while CD163‑positive infiltrating M2 macrophages were green and CD34‑positive vascular endo-
thelial cells displayed as magenta (magnification, x200). VEGFA, vascular endothelial growth factor A; APE1, apurinic/apyrimidinic endodeoxyribonuclease 1.
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in high-grade BCa (25). Choi et al (5) proposed that APE1 
may be used as a non-invasive urinary biomarker for BCa; 
however, its sensitivity and specificity are not satisfying for 
immediate clinical results. Recently, Fishel et al (26) reported 
that APE1 was overexpressed in human BCa tissue and that 
APE1 redox signaling‑specific inhibitor APX3330 was able 
to attenuate the proliferation of BCa cells and increase their 
apoptosis. However, the potential capability of APE1 expres-
sion levels to differentiate between NMIBC and MIBC has not 
been previously reported. The present study suggested an even 
distribution of APE1 expression in both NMIBC and MIBC, 
with no significant difference between the two (P=0.711). 
Furthermore, no significant difference in APE1 expression 
was determined between high-grade and low-grade BCa 
(P=0.744). However, high APE1 expression was associated 
with the presence of LVI and unfavorable prognosis in patients 
with BCa. APE1 expression was also positively correlated with 
VEGFA and CD163+ TAM ratio in BCa tissue.
Previous studies have indicated that high expression of 
APE1 in lung cancer and osteosarcoma is associated with 
upregulated VEGF through hypoxia-inducible factor-1α acti-
vation and retardation of APE1 results in a significant drop 
in VEGF expression (27). Of note, Pignot et al (28) analyzed 
the angiogenic pathways in human transitional cell carcinoma 
of the bladder using a large-scale real-time reverse transcrip-
tion-PCR approach, indicating that VEGFA, MET, C-X-C motif 
chemokine receptor 4 and interleukin‑8 were significantly over-
expressed in tumor samples, but only VEGFA overexpression 
was an independent prognostic factor for overall and disease-free 
survival. This did not align with the present analysis of VEGFA 
expression at the protein level, as no significant prognostic value 
for VEGFA was determined in BCa; perhaps a further study 
with more cases will better indicate the correlation between 
transcriptional levels and protein expression of VEGFA in BCa.
VEGF and its receptors have profound effects on the early 
development and differentiation of both vascular endothelial and 
hematopoietic progenitors. Kloepper et al (29) further suggested 
that when subjecting glioblastoma to anti-VEGF/angiopoietin-2 
blockade, TAMs along the M1 to M2 continuum are being 
reprogrammed toward the M1 phenotype to provide a greater 
survival benefit. This suggested that VEGF may have a novel 
role in immunosuppression by M2 polarization.
Macrophage infiltration is associated with significantly 
better cancer-specific survival in patients with CD163+ 
TAM-associated tumors. A meta-analysis of 1,400 cases of 
BCa including 13 studies further indicated that only CD163+ 
TAMs, not CD68+ TAMs, were closely associated with OS, 
recurrence-free survival and progression-free survival (30). 
Consistent with the present results, macrophage infiltration 
was indicated to be associated with the prognosis of BCa. The 
present study demonstrated through IHC and multiple immu-
nofluorescences staining that a high CD163+ macrophage ratio 
is associated with an unfavorable prognosis.
Recently, Hudson et al (31) published a comparative study 
of 19 glioma specimens with recurrence after treatment. 
Through screening of 96 gene expressions, APE1 expression 
in tumor tissues was significantly increased after treatment. 
In addition, genes linked to immunosuppression, invasion and 
metastasis (glycoprotein nmb, C-C motif chemokine ligand 5 
and killer cell lectin-like receptor C1) and an M2 pheno-
type (CD163) were also detected. The polarized genes were 
significantly upregulated. In 2018, Yan et al (32) reported that 
the APE1‑specific redox inhibitor APX3330 directly affected 
the polarization of M2 macrophages in the role of neurological 
recovery after stroke in type I diabetic rats. However, the 
specific mechanism by which APE1 regulates M2 polarization 
has remained elusive. The present results confirmed a positive 
correlation between APE1, VEGFA and CD163 at the protein 
Table I. Univariate and multivariate COX analysis of the prognosis of IHC marker for OS.
 Univariate Multivariate
 -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
Variable HR 95% CI P-value HR 95% CI P-value
Agea 1.492 0.829-2.687 0.182
Sexb 1.047 0.413-2.654 0.923
Smokingc 0.913 0.479-1.741 0.783
LVId 2.974 1.642-5.387 <0.001
T-stagee 8.279 2.948-23.255 <0.001 12.857 3.883-42.575 <0.001
N-stagef 4.265 2.262-8.045 <0.001
Gradeg 2.201 0.530-9.135 0.277
APE1h 2.797 1.486-5.267 0.001 3.644 1.863-7.129 <0.001
VEGFAi 0.860 0.479-1.544 0.613 0.410 0.217-0.773 0.006
CD163j 2.425 1.300-4.521 0.005 2.883 1.480-5.617 0.002
aAge, ≤65 vs. >65 years; bsex, male vs. female; csmoking: positve smoking history vs. negative smoking history; dLVI, lymphovasular inva-
sion vs. no lymphovascular invasion; eT-stage, Tis and T1 vs. T2, T3 and T4; fN-stage, N0 vs. N1 and N2; ggrade, high grade vs. low grade; 
hAPE1, high APE1 expression vs. low APE1 expression; iVEGFA, high VEGFA expression vs. low VEGFA expression; jCD163, high CD163 
ratio vs. low CD163 ratio. Analysis were performed utilizing logistic regression using the Cox proportional hazards model on SPSS 17.0. 
Area under the curve is shown in Table SV. HR, hazard ratio; VEGFA, vascular endothelial growth factor A; APE1, apurinic/apyrimidinic 
endodeoxyribonuclease 1; LVI, lymphovascular invasion.
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level, suggesting that APE1 may be involved in the regulation 
of macrophage polarization through VEGFA.
In the univariate linear regression analysis performed in the 
present study, VEGFA was indicated to have no association with 
OS but it was a confounding factor in the multivariate analysis. 
This is possibly due to several reasons: i) The number of cases 
was too low to accurately present the association; ii) VEGFA 
may not be a decisive factor on OS in BCa, but may still be a 
contributing factor due to its association with other meaningful 
factors, including APE1 and CD163 expression. Further studies 
on this mechanism will be required to draw a conclusion.
The present study demonstrated that high APE1 expression 
is associated with the presence of LVI in BCa. APE1 expression 
was also determined to be positively associated with VEGFA 
expression and increased infiltration of CD163+ TAM. LVI, 
high APE1 expression and a high ratio of CD163+ TAM in BCa 
may lead to a reduced survival time of patients. The results 
may add valuable insight to optimize models predicting BCa 
prognosis, consequently guiding perioperative treatments that 
benefit patients the most. The present study also indicated that 
there may be a mechanism by which high APE1 expression 
contributes to an increase of M2‑type TAMs by definition as 
CD163+, possibly involving regulation of VEGFA expression 
through its redox function. However, the present results are 
limited in that only patients subjected to radical cystectomy 
were recruited, and studies including patients with broader 
recruitment criteria (not only restricting to patients who under-
went cystectomy but, for example, also those who underwent 
transurethral resection) will provide a better analysis. In addi-
tion, only paraffin‑embedded tissues were assessed and there 
was a lack of fresh tissues, which may limit the conclusions of 
the present study. Further prospective studies with standard-
ized protocols should be performed to fully assess the impact 
of LVI, APE1 and VEGFA expression, as well as the CD163+ 
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Figure 3. Factors influencing the survival of patients with bladder cancer. 
(A-C) Kaplan-Meier survival curves; (A) High expression of APE1 was 
associated with shorter OS; (B) VEGFA expression was not significantly 
associated with OS; (C) a high ratio of CD163+ tumor-associated macrophages 
was associated with shorter OS. (D) ROC curves of APE1, VEGFA and 
CD163 were assessed with T stage and N stage for best prediction efficiency. 
VEGFA, vascular endothelial growth factor A; APE1, apurinic/apyrimidinic 
endodeoxyribonuclease 1; OS, overall survival; ROC, receiver operating 
characteristic; m, months.
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